Ken O'Flynn

1042. Deputy Ken O'Flynn asked the Minister for Health whether any review has been undertaken into regional variation in the use of private ambulance providers by hospitals or hospital groups. [36784/26]

1043. Deputy Ken O'Flynn asked the Minister for Health whether any private ambulance providers currently engaged by HSE-funded hospitals also provide services under other HSE contracts or public procurement arrangements. [36785/26]

1044. Deputy Ken O'Flynn asked the Minister for Health whether any national policy exists governing when hospitals should utilise private ambulance providers instead of National Ambulance Service resources. [36786/26]

1045. Deputy Ken O'Flynn asked the Minister for Health whether any estimate exists of the total annual cost to the State of outsourced non-emergency patient transport services.; and if she will make a statement on the matter. [36787/26]

1046. Deputy Ken O'Flynn asked the Minister for Health the total number of rejected or unpaid pharmacy claims recorded under the General Medical Services Scheme in each year from 2020 to 2026, in tabular form [36795/26]

1047. Deputy Ken O'Flynn asked the Minister for Health the most common categories of rejected pharmacy claims under the General Medical Services Scheme in each year since 2020. [36796/26]

1048. Deputy Ken O'Flynn asked the Minister for Health whether the HSE records the number of rejected claims relating specifically to respiratory medications including salbutamol, ipratropium, steroid inhalers and nebuliser products. [36797/26]

1049. Deputy Ken O'Flynn asked the Minister for Health whether any audit, review, or risk assessment has been conducted examining the patient safety implications of rejected pharmacy claims under the PCRS system in the past five years. [36798/26]

1050. Deputy Ken O'Flynn asked the Minister for Health whether pharmacies are financially disadvantaged where claims are repeatedly rejected due to software or administrative validation issues. [36799/26]

1051. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has conducted any assessment of the potential public health risks associated with long-term exposure to manganese levels between 50 µg/l and 80 µg/l in drinking water. [36800/26]

1052. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has issued any specific guidance for infants, pregnant women, immunocompromised persons or vulnerable groups in areas where manganese levels exceed 50 µg/l. [36801/26]

1053. Deputy Ken O'Flynn asked the Minister for Health the number of manganese exceedance notifications received by the HSE in each year from 2020 to 2026, in tabular form. [36802/26]

1054. Deputy Ken O'Flynn asked the Minister for Health whether the HSE records the geographic location of manganese exceedance notifications received from water suppliers. [36803/26]

1055. Deputy Ken O'Flynn asked the Minister for Health whether any internal protocol, standard operating procedure or risk assessment framework governs how the HSE assesses manganese exceedance notifications on a case-by-case basis. [36804/26]

1056. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has considered establishing a national centralised database of heavy metal exceedances in drinking water and associated public health advice. [36805/26]

1057. Deputy Ken O'Flynn asked the Minister for Health whether any interagency review has taken place between the HSE, EPA and Uisce Éireann regarding public communication on manganese contamination in drinking water. [36806/26]

1058. Deputy Ken O'Flynn asked the Minister for Health whether any cases of suspected illness or adverse health outcomes linked to manganese exposure in drinking water have been reported to the HSE since 2020. [36807/26]

1059. Deputy Ken O'Flynn asked the Minister for Health whether the HSE distinguishes between aesthetic water discolouration complaints and laboratory-confirmed manganese exceedances in its public communications. [36808/26]

1060. Deputy Ken O'Flynn asked the Minister for Health whether the HSE intends to revise or update its July 2024 FAQ guidance on manganese in drinking water. [36809/26]

1070. Deputy Ken O'Flynn asked the Minister for Health the total number of pharmacy claims rejected by the Primary Care Reimbursement Service in each month of 2024 and 2025, in tabular form, broken down by rejection category. [36911/26]

1071. Deputy Ken O'Flynn asked the Minister for Health the percentage of rejected pharmacy claims subsequently resubmitted and approved by the Primary Care Reimbursement Service in 2024 and 2025. [36912/26]

1072. Deputy Ken O'Flynn asked the Minister for Health whether the primary care reimbursement service maintains data on incorrect or overturned claim rejections; and, if so, to provide the figures for 2024 and 2025. [36913/26]

1073. Deputy Ken O'Flynn asked the Minister for Health whether any assessment has been carried out into the financial impact of rejected pharmacy claims on community pharmacies. [36914/26]

1074. Deputy Ken O'Flynn asked the Minister for Health whether any complaints, appeals, or representations were received from pharmacies regarding claim rejection accuracy or consistency in 2024 and 2025; and if so, the number received. [36915/26]

1075. Deputy Ken O'Flynn asked the Minister for Health whether claim rejection rates vary depending on pharmacy software systems used by contractors participating in PCRS schemes [36916/26]